Abstract
Dalbavancin is a lipoglycopeptide approved for the treatment of acute bacterial skin and skin structure infections (ABSSSI). The aim of the study was to evaluate the efficacy and safety in all patients who received at least one administration of dalbavancin. Methods: We carried out a retrospective study of the use of dalbavancin in 55 patients at the Azienda Ospedaliera Ospedali Riuniti Umberto I (Ancona, Italy) from February 2017 to May 2020 and compared “on label” and “off label” use of dalbavancin in ABSSSI and non-ABSSSI. Results: A total of 55 patients were included in the study. The median age was 61 years; 51% had ABSSSI; 24% had prosthetic joint infections, and 14% had osteomyelitis. A total of 53% received a single 1500 mg infusion of dalbavancin, and 18% received a second dose 14 days later; 24% of patients received further doses at 14-day intervals. In 91% of cases, patients achieved clinical objectives with dalbavancin: 96% of patients with ABSSSI and 69% of those with prosthetic joint infections. Conclusions: Dalbavancin was shown to have an excellent tolerability profile and to be a highly successful therapeutic approach even in those cases treated “off-label”.
Highlights
Dalbavancin is a new lipoglycopeptide approved by the European Medicines Agency (EMA) and by the US Food and Drug Administration (FDA) for the treatment of acute bacterial skin and skin structure infections (ABSSSI) in adults [1,2]
It has a spectrum of activity against Gram-positive bacteria, including drug-resistant isolates, such as methicillin-resistant Staphylococcus aureus (MRSA) [3,4]
Several studies of the “offlabel” use of dalbavancin have recently been published. This antibiotic is being used for outpatient parenteral antimicrobial therapy (OPAT) and in infections, such as endocarditis and osteomyelitis, that require long-term antibiotic therapy and long periods of hospitalization [11,12,14,15,16]
Summary
Dalbavancin is a new lipoglycopeptide approved by the European Medicines Agency (EMA) and by the US Food and Drug Administration (FDA) for the treatment of acute bacterial skin and skin structure infections (ABSSSI) in adults [1,2]. Several studies of the “offlabel” use of dalbavancin have recently been published This antibiotic is being used for outpatient parenteral antimicrobial therapy (OPAT) and in infections, such as endocarditis and osteomyelitis, that require long-term antibiotic therapy and long periods of hospitalization [11,12,14,15,16]. The “off-label” use of dalbavancin and the utility of OPAT has been described in patients classified as vulnerable or high-risk for complications (persons who inject drugs or those who lack social support) [17]
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
